10.30
+0.49%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Navamedic A
Its shares trade on Oslo Børs under the ticker NAVA.OL. It has been listed since 31 March 2006. In the fiscal year to 31 December 2025, it reported revenue of NOK 565.4m and a net loss of NOK 23.5m. At that date it held total assets of NOK 741.7m and shareholders' equity of NOK 334.1m.
Navamedic ASA engages in the delivery and marketing of pharmaceutical products to patients, hospitals, and pharmacies. The company is headquartered in Oslo, Oslo. The company went IPO on 2006-03-31. The company is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The firm has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The firm has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 31 Mar 2006
- Website
- navamedic.com ↗
Leadership
Pay as last reported
- Mr. Jostein DavidsenChairman of the Board, since 2017
- Ms. Kathrine Gamborg AndreassenChief Executive Officer, since 2018
- Mr. Lars HjarrandChief Financial Officer
- Mr. Magnus EmmothChief Executive Officer of Navamedic Medtech AB
- Mr. Per-Anders ElvertroChief Scientific Officer
- Mr. Mattias von HaartmanMarketing & Sales Director
- Ms. Annika KollenDirector
- Ms. Asa KornfeldDirector
- Mr. Cheng LuDirector
- Mr. Kjell-Erik NordbyDirector
- Hr. Narve ReitenDirector
- Ms. Inger SolbergDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Navamedic ASA delivers pharmaceutical products to hospitals and pharmacies across Nordic countries and Baltics.
- Navamedic ASA offers a diverse portfolio including prescription, OTC, and medical nutrition products.
- Navamedic ASA has two subsidiaries, Navamedic AB and Novicus Pharma AS, supporting product distribution.
Weaknesses
- Navamedic ASA's business segment is limited to the Pharma division with no other segments.
- Navamedic ASA's product portfolio includes only prescription and OTC pharmaceuticals.
- Navamedic ASA's presence is restricted to Nordic countries, Baltics, and Benelux regions.
Opportunities
- Navamedic ASA can expand its product portfolio to include medical devices and cosmetics.
- Navamedic ASA can grow in the Nordic market with its current distribution network.
- Navamedic ASA can leverage its subsidiaries for further market expansion.
Threats
- Navamedic ASA faces competition from other pharmaceutical suppliers in the Nordic region.
- Navamedic ASA must comply with pharmaceutical regulations in all Nordic countries.
- Navamedic ASA's reliance on the Pharma division could limit growth opportunities.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.